Table 3.

Multivariate analysis of outcomes. 99% confidence intervals shown and p-value <0.01 is considered significant

Outcome	N (Events/Evaluable)	Hazard Ratio (99% CI)	p-value
Non-relapse mortality
Main effect-age			<0.01
60 – 69	189/6922	1.00
40 – 49	23/1591	0.55 (0.35–0.85)	<0.01
50 – 59	86/4855	0.67 (0.52–0.87)	<0.01
≥ 70	75/2063	1.30 (0.99–1.70)	0.06
Karnofsky score ≥90	148/8236	1.00	<0.01
<90	218/7028	1.52 (1.23–1.88)	<0.01
Missing	7/167	2.65 (1.24–5.66)	0.01
HCT-Comorbidity Index 0	54/4093	1.00	<0.01
1–2	109/4778	1.66 (1.20–2.30)	<0.01
≥3	210/6560	2.18 (1.61–2.95)	<0.01
ISS/DSS I-II	131/6612	1.00	<0.01
III	231/8398	1.42 (1.15–1.77)	<0.01
Missing	11/421	1.42 (0.77–2.63)	0.26
Disease status at AHCT, CR	41/2460	1.00	<0.01
VGPR	127/6095	1.27 (0.90–1.81)	0.18
PR	158/5845	1.67 (1.18–2.35)	<0.01
<PR	47/1031	2.93 (1.93–4.46)	<0.01
Relapse/Progression
Main effect-age			0.86
60 – 69	1719/6922	1.00
40 – 49	401/1591	1.00 (0.90–1.12)	0.92
50 – 59	1243/4855	1.03 (0.95–1.10)	0.43
≥ 70	498/2063	1.03 (0.93–1.13)	0.56
ISS/DSS I-II	1426/6612	1.00	<0.01
III	2331/8398	1.36 (1.27–1.46)	<0.01
Missing	104/421	1.27 (1.04–1.56)	0.02
Disease status at AHCT, CR	530/2460	1.00	<0.01
VGPR	1436/6095	1.12 (1.01–1.24)	0.03
PR	1561/5845	1.29 (1.17–1.42)	<0.01
<PR	334/1031	1.70 (1.48–1.95)	<0.01
Cytogenetics, no abnormality	66/3298	1.00	<0.01
High risk	1324/4263	1.88 (1.71–2.07)	<0.01
Standard risk	961/4717	1.05 (0.95–1.16)	0.30
Not tested/unknown	915/3153	1.22 (1.09–1.36)	<0.01
Year of transplant, 2017	454/3628	1.00	<0.01
2013	829/2625	1.19 (1.04–1.36)	0.01
2014	915/2819	1.18 (1.05–1.33)	<0.01
2015	862/2926	1.07 (0.95–1.20)	0.29
2016	801/3433	0.96 (0.86–1.09)	0.54
Progression-free survival
Main effect-age			0.48
60 – 69	1908/6922	1.00
40 – 49	424/1591	0.96 (0.86–1.06)	0.45
50 – 59	1329/4855	0.99 (0.92–1.06)	0.92
≥ 70	573/2063	1.05 (0.96–1.16)	0.24
Karnofsky score ≥90	2170/8236	1.00	<0.01
<90	2011/7028	1.12 (1.05–1.19)	<0.01
Missing	53/167	1.43 (1.09–1.88)	0.01
ISS/DSS I-II	1557/6612	1.00	<0.01
III	2562/8398	1.36 (1.28–1.45)	<0.01
Missing	115/421	1.29 (1.07–1.56)	<0.01
Disease status at AHCT, CR	571/2460	1.00	<0.01
VGPR	1563/6095	1.13 (1.03–1.25)	0.01
PR	1719/5845	1.32 (1.20–1.45)	<0.01
<PR	381/1031	1.78 (1.57–2.03)	<0.01
Cytogenetics, no abnormality	734/3298	1.00	<0.01
High risk	1430/4263	1.82 (1.67–1.99)	<0.01
Standard risk	1061/4717	1.05 (0.95–1.15)	0.33
Not tested/unknown	1009/3153	1.22 (1.09–1.35)	<0.01
Year of transplant, 2017	502/3628	1.00	<0.01
2013	909/2625	1.20 (1.06–1.36)	<0.01
2014	996/2819	1.20 (1.06–1.36)	<0.01
2015	945/2926	1.09 (0.97–1.22)	0.14
2016	882/3433	0.98 (0.88–1.10)	0.73
Overall survival
Main effect-age	659/6992		<0.01
60 – 69	117/1605	1.00
40 – 49	400/4919	0.77 (0.63–0.94)	0.01
50 – 59	227/2084	0.88(0.77–0.99)	0.05
≥ 70	659/6992	1.18(1.02–1.38)	0.03
Karnofsky score ≥90	627/8323	1.33 (1.19–1.48)	<0.01
<90	755/7108	1.83 (1.18–2.82)	<0.01
Missing	21/169	1.33 (1.19–1.48)	<0.01
HCT-Comorbidity Index 0	304/4140	1.00	<0.01
1–2	416/4831	1.16 (1.00–1.34)	0.05
≥3	683/6629	1.33 (1.16–1.52)	<0.01
ISS/DSS I-II	424/6685	1.00	<0.01
III	944/8488	1.77 (1.58–1.99)	<0.01
Missing	35/427	1.36 (0.96–1.92)	0.08
Disease status at AHCT, CR	173/2467	1.00	<0.01
VGPR	507/6148	1.21 (1.02–1.44)	0.03
PR	548/5929	1.37 (1.15–1.62)	<0.01
<PR	175/1056	2.55 (2.07–3.15)	<0.01
Cytogenetics, no abnormality	215/3334	1.00	<0.01
High risk	523/4311	2.07 (1.77–2.42)	<0.01
Standard risk	262/4755	0.87 (0.73–1.04)	0.13
Not tested/unknown	403/3200	1.73 (1.46–2.04)	<0.01

Legend: HCT-CI, hematopoietic cell transplantation-comorbidity index; ISS, International Staging System: DSS, Durie-Salmon staging; VGPR, very good partial response; CR, complete response; AHCT, autologous hematopoietic cell transplantation; PR, partial response